ELTX

Healthcare Biotechnology

Elicio Therapeutics, Inc.

$1.90

-0.02 -1.04% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 5, 2026, live at 3:47 PM ET	1.90

Key Stats

Market Cap

49.94M

Avg Volume

452,314

EPS

-$2.16

52W High

$16.00

52W Low

$1.71

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-1.12

P/B Ratio

5.25

EV/EBITDA

-1.09

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(774.6%)

Return on Assets

(77.9%)

Liquidity & Leverage

Current Ratio

2.77

Quick Ratio

2.55

Debt / Equity

1.78

Total Cash

23.48M

Total Debt

14.15M

About

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

elicio.com